Your search for supplemental oxygen returned 11 results

The approval was based on data from the phase 3 ACTT-2 and COV-BARRIER studies.

The studies evaluated routine clinical practice data from more than 800 hospitals in the US.

The sBLA is supported by data from 4 randomized, controlled studies that evaluated tocilizumab for the treatment of COVID-19 in more than 5500 hospitalized patients.

The update was based on data from the COV-BARRIER study.

Based on efficacy results from 2 phase 3 studies, Lilly has decided to discontinue development of baricitinib for lupus.

The EUA was issued based on 4 randomized controlled clinical trials that evaluated the efficacy and safety of Actemra in more than 5500 hospitalized patients with COVID-19.

Shortly after an EUA was issued, Genentech announced that tocilizumab (marketed under the brand name Actemra) was in shortage.

Actemra (tocilizumab) is an interleukin-6 receptor antagonist.

Kineret is an interleukin-1 receptor antagonist.

InflaRx is working to increase supply of the product in the US as quickly as possible.